The Trump administration has announced nine new pricing agreements with drug manufacturers, a move intended to reduce the cost of prescription medicines for Americans. These agreements reflect President Donald Trump's stated commitment to lowering drug prices.
However, some analyses suggest that for substantial and lasting price reductions, the administration should focus its efforts on international negotiations. The argument is that wealthy foreign governments often suppress drug prices through their own policies, leading to a situation where the United States bears a disproportionate share of the research and development costs for new medicines.
For decades, these foreign governments have allegedly used mechanisms such as price controls, mandatory rebates, and delayed reimbursements. This has resulted in American patients and the U.S. pharmaceutical industry funding a larger portion of global research and development than their economic share would suggest. According to one perspective, U.S. patients account for approximately three-quarters of pharmaceutical profits and over half of global R&D spending.
Proposals that would tie U.S. drug prices to lower international prices, such as "most-favored-nation" pricing, are viewed by some as potentially harmful. Such measures could reduce funding for future research and development, slow the creation of new treatments, negatively impact jobs, and weaken the competitive position of U.S. drugmakers against international rivals.
The administration's strategy, as outlined by some proponents, involves leveraging its negotiating power internationally. This approach has reportedly been applied in past negotiations, such as a deal with the United Kingdom that is said to increase that country's payment for new medicines, thereby reducing the cost burden on the U.S.
Further efforts include investigations into the drug pricing policies of countries like Germany, aiming to establish leverage for negotiating fairer practices. The strategy proposes extending these efforts to other developed nations, including Japan, France, and Switzerland, which are noted for their own price control mechanisms.
Analysis suggests that if other developed countries were to adopt U.S. pricing levels, it could significantly increase global pharmaceutical revenue. This influx of funds, it is argued, could stimulate research and development within the U.S., potentially leading to job creation and the delivery of more affordable, life-saving treatments.